S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Is Frontline's 20% Dividend Too Good To Be True?
Stock market today: World stocks mixed as Wall St inches toward bull market
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Wheat prices jump following collapse of major dam in southern Ukraine
Here’s What’s Driving the Price of Carvana Higher
Nevada Desert more Valuable than Wall Street or Silicon Valley? (Ad)
Tesla: How and Why It Gets To $300
It Is Not Too Late To “Git” On Board With GitLab 
OTCMKTS:SHTDF

Sinopharm Group (SHTDF) Stock Forecast, Price & News

$3.46
0.00 (0.00%)
(As of 06/6/2023 ET)
Compare
Today's Range
$3.46
$3.46
50-Day Range
$2.90
$3.63
52-Week Range
$1.80
$3.63
Volume
N/A
Average Volume
10,150 shs
Market Capitalization
N/A
P/E Ratio
3.47
Dividend Yield
7.51%
Price Target
N/A

SHTDF stock logo

About Sinopharm Group (OTCMKTS:SHTDF) Stock

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Receive SHTDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sinopharm Group and its competitors with MarketBeat's FREE daily newsletter.

SHTDF Stock News Headlines

The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
Sinopharm Group
Nevada Desert more Valuable than Wall Street or Silicon Valley?
It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.
Sinopharm's second Chinese herb shot is potent
See More Headlines

SHTDF Price History

Industry, Sector and Symbol

Industry
Medical Distributors
Sub-Industry
N/A
Current Symbol
OTCMKTS:SHTDF
Phone
N/A
Fax
N/A
Employees
113,234
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Qingming Yu (Age 59)
    Exec. Chairman
    Comp: $964.3k
  • Mr. Yong Liu (Age 54)
    Pres & Exec. Director
    Comp: $963k
  • Mr. Xiuchang Jiang (Age 59)
    CFO & VP
  • Ms. Xiaojuan Li (Age 47)
    Chief Financial Officer
  • Mr. Yijian Wu (Age 53)
    Sec. to the Board, Company Sec. & Authorised Representative
  • Mr. Wanyong Lian (Age 52)
    VP
  • Mr. Shuangjun Xu (Age 54)
    Non-Exec. VP
  • Mr. Maisong Cai (Age 53)
    VP













SHTDF Stock - Frequently Asked Questions

How have SHTDF shares performed in 2023?

Sinopharm Group's stock was trading at $2.53 at the start of the year. Since then, SHTDF shares have increased by 36.8% and is now trading at $3.46.
View the best growth stocks for 2023 here
.

Is Sinopharm Group a good dividend stock?

Sinopharm Group (OTCMKTS:SHTDF) pays an annual dividend of $0.26 per share and currently has a dividend yield of 1.11%. The dividend payout ratio is 26.05%. This payout ratio is at a healthy, sustainable level, below 75%.

What is Sinopharm Group's stock symbol?

Sinopharm Group trades on the OTCMKTS under the ticker symbol "SHTDF."

How do I buy shares of Sinopharm Group?

Shares of SHTDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sinopharm Group's stock price today?

One share of SHTDF stock can currently be purchased for approximately $3.46.

How many employees does Sinopharm Group have?

The company employs 113,234 workers across the globe.

This page (OTCMKTS:SHTDF) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -